Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Metered dose inhaler: past, present, and future

S K Vaswani1, P S Creticos

  • 1The Johns Hopkins University School of Medicine, Division of Allergy and Clinical Immunology, Baltimore, Maryland, USA.

Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology
|February 25, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical trials in allergen immunotherapy in the age group of children and adolescents: current concepts and future needs.

Clinical and translational allergy·2020
Same author

Magnitude of efficacy measurements in grass allergy immunotherapy trials is highly dependent on pollen exposure.

Allergy·2014
Same author

Immunostimulatory sequence DNA linked to the Amb a 1 allergen promotes T(H)1 cytokine expression while downregulating T(H)2 cytokine expression in PBMCs from human patients with ragweed allergy.

The Journal of allergy and clinical immunology·2001
Same author

The consideration of immunotherapy in the treatment of allergic asthma.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2001
Same author

Managing asthma in adults.

The American journal of managed care·2001
Same author

Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity.

The Journal of allergy and clinical immunology·2000

The conventional metered dose inhaler (MDI) faces uncertainty due to a chlorofluorocarbon ban. Newer dry powder inhalers and Freon-free MDIs are emerging as promising replacements for asthma treatment.

Area of Science:

  • Respiratory Medicine
  • Pharmacology
  • Medical Device Technology

Background:

  • Metered dose inhalers (MDIs) have long been used for respiratory diseases.
  • The production ban on chlorofluorocarbons (Freon) threatens the future of conventional MDIs.
  • Asthma caretakers need to be aware of evolving inhaler technologies.

Purpose of the Study:

  • To review aerosolized treatment modalities for asthma management.
  • To focus on metered dose inhalers (MDIs), their propellants, and modifications.
  • To assess the impact of environmental regulations on inhaler technology.

Main Methods:

  • Literature review of metered dose inhaler (MDI) related studies.
  • Utilized the MEDLINE database for English language publications.

Related Experiment Videos

  • Focused on advancements and alternatives in aerosol therapy.

    • Main Results:

    • Dry powder inhalers (DPIs), particularly multi-dose types, show significant promise.
    • Freon-free pressurized metered dose inhalers (MDIs) are being developed.
    • These newer devices are expected to replace conventional Freon-propelled MDIs.

    Conclusions:

    • Dry powder inhalers and Freon-free MDIs are viable alternatives.
    • The transition away from Freon propellants is imminent.
    • Future asthma management will likely rely on these advanced inhaler systems.